Comparative efficacy and safety of low-dose and high-dose cyclophosphamide as induction therapy for lupus nephritis: a network meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Lee, Young Ho | - |
dc.date.accessioned | 2021-08-02T11:30:08Z | - |
dc.date.available | 2021-08-02T11:30:08Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-06 | - |
dc.identifier.issn | 0340-1855 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/13457 | - |
dc.description.abstract | Aim To assess the relative efficacy and safety of low-dose cyclophosphamide (LCYC) and high-dose CYC (HCYC) as induction therapy for lupus nephritis. Methods Bayesian random-effects network meta-analysis was performed to combine direct and indirect evidence from randomized controlled trials (RCTs) examining the efficacy and safety of LCYC, HCYC, and mycophenolate mofetil (MMF) for induction therapy in patients with lupus nephritis. Results Eleven RCTs (1212 patients) were included. MMF and LCYC showed similar overall response rates (OR 1.02, 95% credible interval [CrI] 0.51–2.02), and MMF showed a higher efficacy than HCYC (OR 1.48, 95% CrI 0.99–2.44). Similarly, LCYC showed a higher overall response than HCYC (OR 1.46, 95% CrI 0.83–2.86). Ranking probability based on SUCRA (surface under the cumulative ranking curve) indicated that MMF had the highest probability of being the best treatment for achieving an overall response (SUCRA = 0.7461), followed by LCYC (SUCRA = 0.6978) and HCYC (SUCRA = 0.0561). LCYC showed the highest probability of decreasing the risk of serious infections (SUCRA = 0.8513), followed by MMF (SUCRA = 0.49387) and HCYC (SUCRA = 0.1548). Conclusion LCYC was an efficacious induction treatment for patients with lupus nephritis and had the highest probability of decreasing the risk of serious infections. Higher response rates and a more favorable safety profile suggest that LCYC is a good option for induction treatment in these patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.title | Comparative efficacy and safety of low-dose and high-dose cyclophosphamide as induction therapy for lupus nephritis: a network meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, Sang-Cheol | - |
dc.identifier.doi | 10.1007/s00393-018-0512-8 | - |
dc.identifier.scopusid | 2-s2.0-85050524243 | - |
dc.identifier.wosid | 000472441300001 | - |
dc.identifier.bibliographicCitation | ZEITSCHRIFT FUR RHEUMATOLOGIE, v.78, no.5, pp.467 - 473 | - |
dc.relation.isPartOf | ZEITSCHRIFT FUR RHEUMATOLOGIE | - |
dc.citation.title | ZEITSCHRIFT FUR RHEUMATOLOGIE | - |
dc.citation.volume | 78 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 467 | - |
dc.citation.endPage | 473 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | PULSE INTRAVENOUS CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | MYCOPHENOLATE-MOFETIL | - |
dc.subject.keywordPlus | CONTROLLED-TRIAL | - |
dc.subject.keywordAuthor | Lupus nephritis | - |
dc.subject.keywordAuthor | Cyclophosphamide | - |
dc.subject.keywordAuthor | Network meta-analysis | - |
dc.subject.keywordAuthor | NIH regimen | - |
dc.subject.keywordAuthor | Euroregimen | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s00393-018-0512-8 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.